Table 1.

Baseline characteristics by randomized intervention among all participants and among survivors who participated in post-trial follow-up.

	Randomized				Post-trial Follow-up
	Aspirin (N=19,934)		Placebo (N=19,942)		Aspirin (N=16,913)		Placebo (N=16,769)
	N	%	N	%	N	%	N	%
Age
45-54	12010	60.2	12015	60.2	10392	61.4	10369	61.8
55-64	5876	29.5	5878	29.5	5021	29.7	4930	29.4
65+	2048	10.3	2049	10.3	1500	8.9	1470	8.8
Smoking
Current	2580	12.9	2655	13.3	1917	11.3	1975	11.8
Past	7167	36.0	7098	35.6	6139	36.3	6017	35.9
Never	10171	51.1	10169	51.0	8845	52.3	8765	52.3
BMI (kg/m2)
<25	10069	50.6	10094	50.7	8678	51.3	8587	51.2
25-<30	6158	30.9	6193	31.1	5201	30.8	5202	31.0
30+	3674	18.5	3633	18.2	3024	17.9	2973	17.7
Alcohol use
< 1 drink/wk	11627	58.3	11599	58.2	9688	57.3	9572	57.1
1+ drink/wk	8302	41.7	8338	41.8	7220	42.7	7192	42.9
Physical activity
<1000 kcal/wk	12923	65.7	13071	66.3	10911	65.3	10933	66.0
≥ 1000 kcal/wk	6751	34.3	6632	33.7	5792	34.7	5631	34.0
Menopausal status
Premenopausal	5478	27.6	5495	27.6	4835	28.6	4797	28.7
Perimenopausal	3521	17.7	3628	18.2	2988	17.7	3090	18.5
Postmenopausal, on HT	6037	30.4	5911	29.7	5223	31.0	5050	30.2
Postmenopausal, not on HT	4850	24.4	4854	24.4	3832	22.7	3791	22.7
Family history of cancer
Yes	3529	17.7	3517	17.6	2993	17.7	2930	17.5
No	16405	82.3	16425	82.4	13920	82.3	13839	82.5
Randomized
Vitamin E
Active	9966	50.0	9971	50.0	8464	50.0	8437	50.3
Placebo	9968	50.0	9971	50.0	8449	50.0	8332	49.7